Evidence map›Paper›PMID 42129220›Full record

ArticleNature communications2026

Mechano-metabolic feedback connects tissue fluidity to mitochondrial DNA-dependent immunity in breast cancer.

Andrea Palamidessi, Emanuela Frittoli, Monica Corada, Emanuele Martini, Leonardo Barzaghi, Chiara Milanese, Galina V Beznoussenko, Alessandro Lazzarin, Edoardo N Bellini, Alexander A Mironov and 18 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Andrea Palamidessi *IFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-7134-7023
Emanuela Frittoli *IFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Monica Corada *IFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0001-8220-0871
Emanuele MartiniIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-3375-7726
Leonardo BarzaghiIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-3174-6441
Chiara MilaneseDepartmental Faculty of Medicine and Surgery, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.ORCID http://orcid.org/0000-0001-8696-2603
Galina V BeznoussenkoIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Alessandro LazzarinIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Edoardo N BelliniIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0001-9766-7685
Alexander A MironovIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Zeno LavagninoIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-7247-8084
Serena MagniIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Sara BarozziIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Dario ParazzoliIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0001-8176-9775
Laura TizzoniCancer Genetics Test Laboratory, Cogentech s.r.l. Società Benefit a Socio Unico, Milan, Italy.
Valentina Dall'OlioCancer Genetics Test Laboratory, Cogentech s.r.l. Società Benefit a Socio Unico, Milan, Italy.
Valeria CancilaTumor Immunology Unit, Department of Health Science, University of Palermo, School of Medicine, Palermo, Italy.
Patrizia RomaniDepartment of Molecular Medicine, University of Padua, Padua, Italy.ORCID http://orcid.org/0000-0002-1149-4304
Melody Di BonaMemorial Sloan Kettering Cancer Center, New York, USA.ORCID http://orcid.org/0000-0002-8853-2604
Renata ZobalovaLaboratory of Molecular Therapy, Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-9097-4700
Stepana BoukalovaLaboratory of Molecular Therapy, Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-6478-4604
Mattia ReditiIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-6713-2599
Pier G MastroberardinoDepartment of Molecular Genetics, Erasmus MC, Rotterdam DR, the Netherlands.
Jiri NeuzilLaboratory of Molecular Therapy, Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-2478-2460
Marco FoianiIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0003-4795-834X
Sirio DupontDepartment of Molecular Medicine, University of Padua, Padua, Italy.ORCID http://orcid.org/0000-0002-6869-1966
Claudio TripodoIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
Giorgio ScitaIFOM-ETS, The AIRC Institute of Molecular Oncology, Milan, Italy. Giorgio.Scita@ifom.eu.ORCID http://orcid.org/0000-0001-7984-1889

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) AIRC 5x1000 (#22759)EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101071470NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Why some tumors respond to immunotherapy ("hot" tumors) while others remain resistant ("cold" tumors) is a central challenge in oncology. Elevated RAB5A-dependent endocytosis drives tissue fluidization during the transition to invasive breast carcinoma, but its immunological consequences are unclear. Here we show that RAB5A-driven fluidization induces a mechano-metabolic stress response that disrupts the AMPK-AKAP1-DRP1 mitochondrial fission pathway, causing mitochondrial elongation. RAB5A vesicles interact with hyperfused mitochondria and promote BAX/BAK-dependent pore formation, leading to limited mitochondrial outer membrane permeabilization. This sub-lethal event is amplified by palmitoylated GASDERMIN A oligomerization on mitochondria, establishing a positive feedback loop. The resulting release of mitochondrial DNA activates the cGAS-STING innate immune pathway and drives a hyperinflammatory state. Consequently, RAB5A-expressing tumors in immunocompetent mice grow more slowly, show increased immune infiltration, and display enhanced sensitivity to immune-checkpoint blockade in a BAX/BAK-, cGAS/STING-, and mtDNA-dependent manner. These findings connect mechanical stress, mitochondrial dynamics, and innate immunity, revealing strategies to potentiate antitumor immunotherapy.

Indexed as

Breast NeoplasmsDNA, MitochondrialAnimalsCell Line, TumorcGAS-STING Signaling PathwayDynaminsFeedback, PhysiologicalFemaleHumansImmunity, InnateMembrane ProteinsMiceMitochondriaMitochondrial Dynamicsrab5 GTP-Binding ProteinsSTING ProteinDNA, MitochondrialDynaminsMembrane Proteinsrab5 GTP-Binding ProteinsSTING Protein

Identifiers

PMID42129220
PMCPMC13377117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.